SCHEMBL1463445

SCHEMBL1463445

O=C(C1CCCCC1)N1CC2CNCC(C2)C1

nearest known ligand 0.83

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ CHRNB2 P17787 15/20 0.83
▸ CHRNA3 P32297 15/20 0.83
▸ CHRNA4 P43681 15/20 0.83
▸ CHRNB4 P30926 14/20 0.83
▸ CHRNA7 P36544 14/20 0.83
▸ CHRNB3 Q05901 1/20 0.58
▸ CHRNA6 Q15825 1/20 0.58
▸ HSD11B1 P28845 4/20 0.56
▸ MEN1 O00255 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ HSD11B2 P80365 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1463847 0.98 CHRNB2 (0.86) CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7
SCHEMBL1463672 0.95 CHRNB2 (0.86) CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7
SCHEMBL13833626 0.91 CHRNB2 (0.68) CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7
SCHEMBL1463858 0.91 CHRNB2 (1.00) CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7
SCHEMBL1464577 0.81 CHRNB2 (0.81) CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7
SCHEMBL12744821 0.81 CHRNA4 (0.64) CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7
SCHEMBL13694275 0.80 CHRNB2 (0.62) CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7
SCHEMBL1464046 0.79 CHRNB2 (0.85) CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7
SCHEMBL1711084 0.79 CHRNB2 (0.87) CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7
SCHEMBL1463547 0.79 CHRNB2 (0.71) CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110071180-A1 SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES TARGACEPT, INC. (US) 2011-03-24 — — US claimed
EP-2257549-A1 NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOAL KANES Targacept Inc. (US) 2010-12-08 — — EP claimed
WO-2009111550-A1 NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOAL KANES TARGACEPT, INC. (US) 2009-09-11 — — WO claimed
US-9580434-B2 Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes ATTENUA, INC. (US) 2017-02-28 — — US disclosed
US-20160039833-A1 NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES CATALYST BIOSCIENCES, INC. 2016-02-11 — — US disclosed
US-20150080576-A1 SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES TARGACEPT INC (US) 2015-03-19 — — US disclosed
US-8921410-B2 Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes TARGACEPT, INC. (US) 2014-12-30 — — US disclosed
US-8859609-B2 Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes TARGACEPT, INC. (US) 2014-10-14 — — US disclosed
US-20130005789-A1 Nicotinic Acetylcholine Receptor Sub-Type Selective Amides of Diazabicycloalkanes TARGACEPT, INC. (US) 2013-01-03 — — US disclosed
US-20120289572-A1 Nicotinic Acetylcholine Receptor Sub-Type Selective Amides of Diazabicycloalkanes TARGACEPT, INC. (US) 2012-11-15 — — US disclosed
US-8268860-B2 Sub-type selective amides of diazabicycloalkanes TARGACEPT, INC. (US) 2012-09-18 — — US disclosed
US-8268860-B2 Sub-type selective amides of diazabicycloalkanes TARGACEPT, INC. (US) 2012-09-18 — — US disclosed
US-8114889-B2 Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes TARGACEPT, INC. (US) 2012-02-14 — — US disclosed
US-20110071180-A1 SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES TARGACEPT, INC. (US) 2011-03-24 — — US disclosed
EP-2257549-A1 NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOAL KANES Targacept Inc. (US) 2010-12-08 — — EP disclosed
US-20100173932-A1 SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES TARGACEPT, INC. (US) 2010-07-08 — — US disclosed
US-20100173932-A1 SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES TARGACEPT, INC. (US) 2010-07-08 — — US disclosed
US-20100081683-A1 NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES TARGCEPT INC. (US) 2010-04-01 — — US disclosed
WO-2009111550-A1 NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOAL KANES TARGACEPT, INC. (US) 2009-09-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289572-A1 Nicotinic Acetylcholine Receptor Sub-Type Selective Amides of Diazabicycloalkanes CHRNA2, CHRNE, CHRNA7 CHRNB2 5/4885CHRNA3 7/4885CHRNA4 4/4885
US-20130005789-A1 Nicotinic Acetylcholine Receptor Sub-Type Selective Amides of Diazabicycloalkanes CHRNA2, CHRNE, CHRNA7 CHRNB2 5/4885CHRNA3 7/4885CHRNA4 4/4885
US-20150080576-A1 SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES CHRNA4, CHRNA2, CHRNE CHRNB2 5/4885CHRNA3 7/4885CHRNA4 1/4885
US-20110071180-A1 SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES CHRNA7, CHRNA2, CHRNA5 CHRNB2 4/4885CHRNA3 8/4885CHRNA4 6/4885
US-20100081683-A1 NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES CHRNA7, CHRNE, CHRNA2 CHRNB2 4/4885CHRNA3 13/4885CHRNA4 5/4885
US-20100173932-A1 SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES CHRNA4, CHRNA2, CHRNE CHRNB2 5/4885CHRNA3 7/4885CHRNA4 1/4885
US-20160039833-A1 NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES CHRNA2, CHRNE, CHRNA7 CHRNB2 5/4885CHRNA3 7/4885CHRNA4 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback